Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19

Liliana Cárdenas; Ali Aymen Abdullah; Gabriela Jaramillo; Paúl Cárdenas; Gabriela Gálvez; Fernando Hidalgo

doi:10.63600/VDCJET22

Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19

Liliana Cárdenas
, Ali Aymen Abdullah^*
, Gabriela Jaramillo
, Paúl Cárdenas
, Gabriela Gálvez
, Fernando Hidalgo

^*Corresponding author for this work

Hospital Eugenio Espejo

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Identifying risk factors is of utmost importance in patients with cardiovascular risk, even more so in those with extremely high risk, who still present with complications despite receiving treatment as secondary prevention. We hypothesized that patients with very high cardiovascular risk would have genetic resistance to the antiplatelet agent clopidogrel. We performed a cross-sectional descriptive study that included 58 patients with the CYP2C19 genotype in the coronary care unit of the hospital, who were divided into two groups: resistant and non-resistant to therapy. We confirmed that patients in extremely high cardiovascular risk had more genetic resistance to clopidogrel, which caused secondary prevention failure, so they would benefit from individualizing antiplatelet therapy.

Translated title of the contribution	Resistencia al clopidogrel en pacientes con extremado alto riesgo cardiovascular con genotipo CYP2C19
Original language	English
Pages (from-to)	134-137
Number of pages	4
Journal	Revista de la Federacion Argentina de Cardiologia
Volume	52
Issue number	3
DOIs	https://doi.org/10.63600/VDCJET22
State	Published - 28 Sep 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cytochrome P-450 CYP2C19
cardiovascular disease
clopidogrel
drug resistance
platelet antiaggregants

Access to Document

10.63600/VDCJET22

Cite this

@article{16abd78df6704c27aa7cb30d23275dc1,

title = "Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19",

abstract = "Identifying risk factors is of utmost importance in patients with cardiovascular risk, even more so in those with extremely high risk, who still present with complications despite receiving treatment as secondary prevention. We hypothesized that patients with very high cardiovascular risk would have genetic resistance to the antiplatelet agent clopidogrel. We performed a cross-sectional descriptive study that included 58 patients with the CYP2C19 genotype in the coronary care unit of the hospital, who were divided into two groups: resistant and non-resistant to therapy. We confirmed that patients in extremely high cardiovascular risk had more genetic resistance to clopidogrel, which caused secondary prevention failure, so they would benefit from individualizing antiplatelet therapy.",

keywords = "Cytochrome P-450 CYP2C19, cardiovascular disease, clopidogrel, drug resistance, platelet antiaggregants",

author = "Liliana C{\'a}rdenas and Abdullah, \{Ali Aymen\} and Gabriela Jaramillo and Pa{\'u}l C{\'a}rdenas and Gabriela G{\'a}lvez and Fernando Hidalgo",

year = "2023",

month = sep,

day = "28",

doi = "10.63600/VDCJET22",

language = "Ingl{\'e}s",

volume = "52",

pages = "134--137",

journal = "Revista de la Federacion Argentina de Cardiologia",

issn = "0326-646X",

publisher = "Federacion Argentina de Cardiologia",

number = "3",

}

TY - JOUR

T1 - Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19

AU - Cárdenas, Liliana

AU - Abdullah, Ali Aymen

AU - Jaramillo, Gabriela

AU - Cárdenas, Paúl

AU - Gálvez, Gabriela

AU - Hidalgo, Fernando

PY - 2023/9/28

Y1 - 2023/9/28

N2 - Identifying risk factors is of utmost importance in patients with cardiovascular risk, even more so in those with extremely high risk, who still present with complications despite receiving treatment as secondary prevention. We hypothesized that patients with very high cardiovascular risk would have genetic resistance to the antiplatelet agent clopidogrel. We performed a cross-sectional descriptive study that included 58 patients with the CYP2C19 genotype in the coronary care unit of the hospital, who were divided into two groups: resistant and non-resistant to therapy. We confirmed that patients in extremely high cardiovascular risk had more genetic resistance to clopidogrel, which caused secondary prevention failure, so they would benefit from individualizing antiplatelet therapy.

AB - Identifying risk factors is of utmost importance in patients with cardiovascular risk, even more so in those with extremely high risk, who still present with complications despite receiving treatment as secondary prevention. We hypothesized that patients with very high cardiovascular risk would have genetic resistance to the antiplatelet agent clopidogrel. We performed a cross-sectional descriptive study that included 58 patients with the CYP2C19 genotype in the coronary care unit of the hospital, who were divided into two groups: resistant and non-resistant to therapy. We confirmed that patients in extremely high cardiovascular risk had more genetic resistance to clopidogrel, which caused secondary prevention failure, so they would benefit from individualizing antiplatelet therapy.

KW - Cytochrome P-450 CYP2C19

KW - cardiovascular disease

KW - clopidogrel

KW - drug resistance

KW - platelet antiaggregants

UR - https://www.scopus.com/pages/publications/105018854883

U2 - 10.63600/VDCJET22

DO - 10.63600/VDCJET22

M3 - Artículo

AN - SCOPUS:105018854883

SN - 0326-646X

VL - 52

SP - 134

EP - 137

JO - Revista de la Federacion Argentina de Cardiologia

JF - Revista de la Federacion Argentina de Cardiologia

IS - 3

ER -

Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this